BridgeBio Pharma Inc. (BBIO) Announces Commercial Progress, Program Updates, and 2025 Milestones

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 10/11/2026

1. HUM
2. SPCX
3. ALHC
4. T
5. PEP
6. AXP
7. TMUS
8. SPY
9. CVS
10. UNH

Go back to BridgeBio Pharma Inc. (BBIO) Announces Commercial Progress, Program Updates, and 2025 Milestones

BridgeBio Announces Commercial Progress, Program Updates, and 2025 Milestones

January 13, 2025 11:00 AM EST

- Remarkable early Attruby demand: 430 scripts written by 248 unique HCPs since FDA approval with broad uptake across academic centers and community centers in all patient types

- Fully enrolled three major market Phase 3 clinical trials: FORTIFY (BBP-418 for LGMD2I/R9); CALIBRATE (encaleret for ADH1); and PROPEL 3 (infigratinib for Achondroplasia)

- Well-financed to launch Attruby and read out major market Phase 3 trials: $406M in cash as of last quarter, received $500M upon acoramidis FDA approval from royalty facility, and anticipate $105M in regulatory milestones in 1H 2025 from acoramidis Europe and... More